CEL-SCI Corporation ("CEL-SCI" or the "Company") , a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced best-efforts offering of 16,000,000 shares of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback